Combination antiretroviral therapy (ART) can suppress plasma HIV to undetectable levels, allowing HIV-infected individuals who are treated early a nearly normal life span. Despite the clear ability of ART to prevent morbidity and mortality, it is not curative. Even in individuals who have full suppression of viral replication on ART, there are resting memory CD4+ T cells that harbor stably integrated HIV genomes, which are capable of producing infectious virus upon T cell activation. This latent viral reservoir is considered the primary obstacle to the development of an HIV cure, and recent efforts in multiple areas of HIV research have been brought to bear on the development of strategies to eradicate or develop a functional cure for HIV. Reviews in this series detail progress in our understanding of the molecular and cellular mechanisms of viral latency, efforts to accurately assess the size and composition of the latent reservoir, the characterization and development of HIV-targeted broadly neutralizing antibodies and cytolytic T lymphocytes, and animal models for the study HIV latency and therapeutic strategies.
Janet D. Siliciano, Robert F. Siliciano
Title and authors | Publication | Year |
---|---|---|
HIV-1 latency: From acquaintance to confidant
Yang C, Tong L, Xue J |
Journal of Virus Eradication | 2025 |
Immunocapture of cell surface proteins embedded in HIV envelopes uncovers considerable virion genetic diversity associated with different source cell types.
Sabour S, Li JF, Lipscomb JT, Santos Tino AP, Johnson JA |
PloS one | 2024 |
SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity
Daly MB, Dinh C, Holder A, Rudolph D, Ruone S, Swaims-Kohlmeier A, Khalil G, Sharma S, Mitchell J, Condrey J, Kim D, Pan Y, Curtis K, Williams P, Spreen W, Heneine W, García-Lerma JG |
Nature Communications | 2024 |
CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice.
Dash PK, Chen C, Kaminski R, Su H, Mancuso P, Sillman B, Zhang C, Liao S, Sravanam S, Liu H, Waight E, Guo L, Mathews S, Sariyer R, Mosley RL, Poluektova LY, Caocci M, Amini S, Gorantla S, Burdo TH, Edagwa B, Gendelman HE, Khalili K |
Proceedings of the National Academy of Sciences | 2023 |
Genetic variation of the HIV-1 subtype C transmitted/founder viruses long terminal repeat elements and the impact on transcription activation potential and clinical disease outcomes
Madlala P, Mkhize Z, Naicker S, Khathi SP, Maikoo S, Gopee K, Dong KL, Ndung\u2019u T |
PLoS pathogens | 2023 |
The Association between CCL5/RANTES SNPs and Susceptibility to HIV-1 Infection: A Meta-Analysis
Silva MJ, Marinho RL, dos Santos PA, dos Santos CS, Ribeiro LR, Rodrigues YC, Lima KV, Lima LN |
Viruses | 2023 |
FBXO34 promotes latent HIV-1 activation by post-transcriptional modulation
Yang X, Zhao X, Zhu Y, Xun J, Wen Q, Pan H, Yang J, Wang J, Liang Z, Shen X, Liang Y, Lin Q, Liang H, Li M, Chen J, Jiang S, Xu J, Lu H, Zhu H |
Emerging Microbes & Infections | 2022 |
HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection
Yik Lim Kok, Valentina Vongrad, Sandra E. Chaudron, Mohaned Shilaih, Christine Leemann, Kathrin Neumann, Katharina Kusejko, Francesca Di Giallonardo, Herbert Kuster, Dominique Braun, Roger D. Kouyos, Huldrych F. Günthard, Karin J Metzner |
JCI Insight | 2021 |
Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System
H Nguyen, H Wilson, S Jayakumar, V Kulkarni, S Kulkarni |
Viruses | 2021 |
Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States
K Dubé, J Kanazawa, L Dee, J Taylor, JA Sauceda, S Gianella, D Smith, SG Deeks, MJ Peluso |
AIDS Research and Therapy | 2021 |
Pathways towards human immunodeficiency virus elimination
PK Dash, BD Kevadiya, H Su, MG Banoub, HE Gendelman |
EBioMedicine | 2020 |
CD8+ T cells in HIV control, cure and prevention
DR Collins, GD Gaiha, BD Walker |
Nature Reviews Immunology | 2020 |
Elite suppressors have low frequencies of intact HIV-1 proviral DNA
AK Kwaa, CC Garliss, KD Ritter, GM Laird, JN Blankson |
AIDS | 2020 |
Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus
R Sivanandham, AJ Kleinman, P Sette, E Brocca-Cofano, SM Venkatraman, BB Policicchio, T He, C Xu, J Swarthout, Z Wang, I Pandrea, C Apetrei, G Silvestri |
Journal of virology | 2020 |
A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region
A Hajduczki, DT Danielson, DS Elias, V Bundoc, AW Scanlan, EA Berger |
Frontiers in Cellular and Infection Microbiology | 2020 |
Hypoxic microenvironment shapes HIV-1 replication and latency
X Zhuang, I Pedroza-Pacheco, I Nawroth, AE Kliszczak, A Magri, W Paes, CO Rubio, H Yang, M Ashcroft, D Mole, P Balfe, P Borrow, JA McKeating |
2020 | |
Immune activation correlates with and predicts CXCR4 co-receptor tropism switch in HIV-1 infection
BJ Connell, LE Hermans, AM Wensing, I Schellens, PJ Schipper, PM van Ham, DT de Jong, S Otto, T Mathe, R Moraba, JA Borghans, MA Papathanasopoulos, Z Kruize, FW Venter, NA Kootstra, H Tempelman, K Tesselaar, M Nijhuis |
Scientific Reports | 2020 |
Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice
PK Dash, R Kaminski, R Bella, H Su, S Mathews, TM Ahooyi, C Chen, P Mancuso, R Sariyer, P Ferrante, M Donadoni, JA Robinson, B Sillman, Z Lin, JR Hilaire, M Banoub, M Elango, N Gautam, RL Mosley, LY Poluektova, JE McMillan, AN Bade, S Gorantla, IK Sariyer, TH Burdo, WB Young, S Amini, J Gordon, JM Jacobson, B Edagwa, K Khalili, HE Gendelman |
Nature Communications | 2019 |
Population Structure and Implications on the Genetic Architecture of HIV-1 Phenotypes Within Southern Africa
PK Thami, ER Chimusa |
Frontiers in Genetics | 2019 |
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
G Mylvaganam, AG Yanez, M Maus, BD Walker |
Frontiers in immunology | 2019 |
Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer’s disease?
T Fulop, JM Witkowski, A Larbi, A Khalil, G Herbein, EH Frost |
Journal of Neurovirology | 2019 |
Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles
C Tumiotto, BM Alves, P Recordon-Pinson, M Jourdain, P Bellecave, GL Guidicelli, J Visentin, F Bonnet, M Hessamfar, D Neau, J Sanchez, C Brander, M Sajadi, L Eyzaguirre, EA Soares, JP Routy, MA Soares, H Fleury, C Apetrei |
PloS one | 2019 |
Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses
B Sahay, A Aranyos, M Mishra, A McAvoy, M Martin, R Pu, S Shiomitsu, K Shiomitsu, M Dark, M Sanou, S Roff, M Rathore, J Yamamoto |
Viruses | 2019 |
Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection
ZM Ndhlovu, SW Kazer, T Nkosi, F Ogunshola, DM Muema, G Anmole, SA Swann, A Moodley, K Dong, T Reddy, MA Brockman, AK Shalek, T Ndungu, BD Walker |
Science Translational Medicine | 2019 |
gamma/delta T cells: an immunotherapeutic approach for HIV cure strategies
Carolina Garrido, Matthew Clohosey, Chloe Whitworth, Michael Hudgens, David M. Margolis, Natalia Soriano-Sarabia |
JCI Insight | 2018 |
Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC + CD4 + cell levels: a surrogate marker candidate of HIV-induced intestinal damage
MJ Ploquin, A Casrouge, Y Madec, N Noël, B Jacquelin, N Huot, D Duffy, SP Jochems, L Micci, C Lécuroux, F Boufassa, T Booiman, T Garcia-Tellez, M Ghislain, RL Grand, O Lambotte, N Kootstra, L Meyer, C Goujard, M Paiardini, ML Albert, M Müller-Trutwin |
Journal of the International AIDS Society | 2018 |
The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation
X Zhang, J Lin, T Liang, H Duan, X Tan, , L Li, S Liu |
Acta Pharmacologica Sinica | 2018 |
HIV Tat/P-TEFb Interaction: A Potential Target for Novel Anti-HIV Therapies
K Asamitsu, K Fujinaga, T Okamoto |
Molecules (Basel, Switzerland) | 2018 |
Mystique versus Machismo: Sex Differences in HIV Infection
EP Scully |
Pathogens and Immunity | 2018 |
Design, synthesis, and biological evaluation of AV6 derivatives as novel dual reactivators of latent HIV-1
M Ao, Z Pan, Y Qian, B Tang, Z Feng, H Fang, Z Wu, J Chen, Y Xue, M Fang |
RSC Advances | 2018 |
Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal
CA Marian, M Stoszko, L Wang, MW Leighty, E de Crignis, CA Maschinot, J Gatchalian, BC Carter, B Chowdhury, DC Hargreaves, JR Duvall, GR Crabtree, T Mahmoudi, EC Dykhuizen |
Cell Chemical Biology | 2018 |
Visualization of HIV-1 RNA Transcription from Integrated HIV-1 DNA in Reactivated Latently Infected Cells
O Ukah, M Puray-Chavez, P Tedbury, A Herschhorn, J Sodroski, S Sarafianos |
Viruses | 2018 |
Counteracting Akt Activation by HIV Protease Inhibitors in Monocytes/Macrophages
S Pasquereau, A Kumar, W Abbas, G Herbein |
Viruses | 2018 |
Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation
U Mbonye, B Wang, G Gokulrangan, W Shi, S Yang, J Karn |
The Journal of biological chemistry | 2018 |
Anti-inflammatory effects of aprepitant co-administration with cART regimen containing ritonavir in HIV infected adults
Sergei Spitsin, Pablo Tebas, Jeffrey Barrett, Vasiliki Pappa, Deborah Kim, Deanne Taylor, Dwight Evans, Steven D. Douglas |
JCI Insight | 2017 |
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy
A Tsai, A Irrinki, J Kaur, T Cihlar, G Kukolj, DD Sloan, JP Murry, G Silvestri |
Journal of virology | 2017 |
The Role of Caveolin 1 in HIV Infection and Pathogenesis
A Mergia |
Viruses | 2017 |
Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral Reservoirs
S Pasquereau, A Kumar, G Herbein |
Viruses | 2017 |
Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells
R Sampath, NW Cummins, S Natesampillai, GD Bren, TD Chung, J Baker, K Henry, A Pagliuzza, AD Badley, RF Speck |
PloS one | 2017 |
A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter
J Wu, M Ao, R Shao, H Wang, D Yu, M Fang, X Gao, Z Wu, Q Zhou, Y Xue |
Scientific Reports | 2017 |
Conserved HIV Epitopes for an Effective HIV Vaccine
B Sahay, CQ Nguyen, JK Yamamoto |
Journal of Clinical & Cellular Immunology | 2017 |
RNA Interference Therapies for an HIV-1 Functional Cure
R Scarborough, A Gatignol |
Viruses | 2017 |
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
SP Fuchs, RC Desrosiers |
Molecular Therapy - Methods & Clinical Development | 2016 |
Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8 + T Cells
KN Smith, RB Mailliard, PA Piazza, W Fischer, BT Korber, RJ Fecek, D Ratner, P Gupta, JI Mullins, CR Rinaldo |
mBio | 2016 |
TNF and HIV-1 Nef: An Intimate Interplay
G Herbein |
EBioMedicine | 2016 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |